Phase 3 Leukaemia Trial, Recruiting NCT06345365 Sponsor: Zhongnan Hospital Condition: Leukaemia
Back to Leukaemia

Phase 3 Leukaemia Trial, Recruiting

NCT06345365
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with primary acute myeloid leukaemia (AML), confirmed through bone marrow testing
  • People aged between 18 and 75 years old
  • People whose liver and kidney function test results fall within acceptable ranges as defined by the trial
  • People whose heart function shows a pumping efficiency of at least 50%, with heart marker blood tests also within acceptable ranges
  • People who are generally able to carry out basic daily activities, rated as 0–2 on a standard physical wellbeing scale used by doctors
  • People who have given their written consent to participate, either personally or through a family member

Who may not be able to join:

  • People who have a known allergy or medical reason to avoid any of the medications used in this trial
  • People who also have a condition called myelofibrosis (scarring of the bone marrow)
  • People with serious heart conditions, including previous heart attack or heart failure
  • People who have another type of cancer affecting a different part of the body
  • People who have active tuberculosis or who are HIV-positive
  • People who have another blood disorder at the same time as their AML diagnosis
  • People who are pregnant or currently breastfeeding
  • People who are unable to understand or follow the trial's instructions and requirements
  • People who have previously had a serious reaction or intolerance to medications similar to those used in this trial
  • People who are currently taking part in another clinical trial
  • People with any other condition that the trial team determines would prevent safe participation (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Fuling Zhou, Wuhan University

Phone: 027-67813137

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Zhongnan Hospital
Registry
ClinicalTrials.gov
Start date
18 January 2024
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete remission rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov